Tag: disease

Posted on

Autoimmune disease preceding amyotrophic lateral sclerosis: An epidemiologic study.

Related Articles

Autoimmune disease preceding amyotrophic lateral sclerosis: An epidemiologic study.

Neurology. 2013 Aug 14;

Authors: Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ

Abstract
OBJECTIVE: To study whether the risk of amyotrophic lateral sclerosis (ALS) is increased in people with prior autoimmune disease.
METHODS: An all-England hospital record-linkage dataset spanning 1999-2011 was used. Cohorts were constructed of people with each of a range of autoimmune diseases; the incidence of ALS in each disease cohort was compared with the incidence of ALS in a cohort of individuals without prior admission for the autoimmune disease.
RESULTS: There were significantly more cases than expected of ALS associated with a prior diagnosis of asthma, celiac disease, younger-onset diabetes (younger than 30 years), multiple sclerosis, myasthenia gravis, myxedema, polymyositis, Sjögren syndrome, systemic lupus erythematosus, and ulcerative colitis.
CONCLUSIONS: Autoimmune disease associations with ALS raise the possibility of shared genetic or environmental risk factors.

PMID: 23946298 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Posted on

Day-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary disease.

Related Articles

Day-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary disease.

Int J Chron Obstruct Pulmon Dis. 2013;8:273-86

Authors: Kocks JW, van den Berg JW, Kerstjens HA, Uil SM, Vonk JM, de Jong YP, Tsiligianni IG, van der Molen T

Abstract
BACKGROUND: Exacerbations of chronic obstructive pulmonary disease (COPD) are a major burden to patients and to society. Little is known about the possible role of day-to-day patient-reported outcomes during an exacerbation. This study aims to describe the day-to-day course of patient-reported health status during exacerbations of COPD and to assess its value in predicting clinical outcomes.
METHODS: Data from two randomized controlled COPD exacerbation trials (n = 210 and n = 45 patients) were used to describe both the feasibility of daily collection of and the day-to-day course of patient-reported outcomes during outpatient treatment or admission to hospital. In addition to clinical parameters, the BORG dyspnea score, the Clinical COPD Questionnaire (CCQ), and the St George’s Respiratory Questionnaire were used in Cox regression models to predict treatment failure, time to next exacerbation, and mortality in the hospital study.
RESULTS: All patient-reported outcomes showed a distinct pattern of improvement. In the multivariate models, absence of improvement in CCQ symptom score and impaired lung function were independent predictors of treatment failure. Health status and gender predicted time to next exacerbation. Five-year mortality was predicted by age, forced expiratory flow in one second % predicted, smoking status, and CCQ score. In outpatient management of exacerbations, health status was found to be less impaired than in hospitalized patients, while the rate and pattern of recovery was remarkably similar.
CONCLUSION: Daily health status measurements were found to predict treatment failure, which could help decision-making for patients hospitalized due to an exacerbation of COPD.

PMID: 23766644 [PubMed – in process]

View full post on pubmed: asthma

Posted on

The rabbit as a model for studying lung disease and stem cell therapy.

The rabbit as a model for studying lung disease and stem cell therapy.

Biomed Res Int. 2013;2013:691830

Authors: Kamaruzaman NA, Kardia E, Kamaldin N’, Latahir AZ, Yahaya BH

Abstract
No single animal model can reproduce all of the human features of both acute and chronic lung diseases. However, the rabbit is a reliable model and clinically relevant facsimile of human disease. The similarities between rabbits and humans in terms of airway anatomy and responses to inflammatory mediators highlight the value of this species in the investigation of lung disease pathophysiology and in the development of therapeutic agents. The inflammatory responses shown by the rabbit model, especially in the case of asthma, are comparable with those that occur in humans. The allergic rabbit model has been used extensively in drug screening tests, and this model and humans appear to be sensitive to similar drugs. In addition, recent studies have shown that the rabbit serves as a good platform for cell delivery for the purpose of stem-cell-based therapy.

PMID: 23653896 [PubMed – in process]

View full post on pubmed: asthma

Posted on

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Umeclidinium bromide/Vilanterol;   Drug: Placebo ACCUHALER/DISKUS;   Drug: Fluticasone propionate/Salmeterol;   Drug: Placebo NDPI
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Not yet recruiting – verified April 2013

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted on

Programs address cardiovascular disease, immunization, asthma and reducing … – The FINANCIAL

Programs address cardiovascular disease, immunization, asthma and reducing …
The FINANCIAL
Each pilot program addresses a region-specific health issue such as heart disease and diabetes, childhood immunization, asthma and respiratory disease management, and patient compliance and retention. “GE recognizes there is a critical need in the U.S. …

and more »

View full post on asthma – Google News